𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Serous ovarian tumors of low malignant potential with peritoneal implants

✍ Scribed by David M. Gershenson; Elvio G. Silva


Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
943 KB
Volume
65
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Ovarian serous borderline tumors with in
✍ David M. Gershenson; Elvio G. Silva; Lawrence Levy; Thomas W. Burke; Judith K. W πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 324 KB πŸ‘ 2 views

multivariate regression analyses also were performed. University of Texas M. D. Anderson Cancer Cen-RESULTS. Median follow-up time was 111 months. Four of 7 evaluable patients ter, Houston, Texas. who had second-look surgery (57%) had a response to chemotherapy. Twelve of

Serous borderline tumors of the ovary wi
✍ David M. Gershenson; Elvio G. Silva; Guillermo Tortolero-Luna; Charles Levenback πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 279 KB πŸ‘ 2 views

## BACKGROUND. The authors conducted this study to update their experience with patients who have ovarian serous borderline tumors with noninvasive peritoneal implants, with the objectives of gaining additional insight into the biologic behavior of these tumors and understanding better the effects

Aberrant promoter methylation of multipl
✍ Andrew Wiley; Dionyssios Katsaros; Haigang Chen; Irene A. Rigault de la Longrais πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 217 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Methylation‐mediated suppression of detoxification, DNA repair, and tumor suppressor genes has been implicated in cancer development and progression. Studies also have indicated that concordant methylation of multiple genes (methylator phenotypes), rather than a single g

Ovarian papillary serous tumors of low m
✍ Alexander W. Kennedy; William R. Hart πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 900 KB

## Background: The clinical outcome of patients with ovarian serous tumors of low malignant potential (lmp) remains controversial, especially for those with extraovarian disease. we retrospectively reviewed our experience to study this question further, to assess the safety of conservative manageme